Abstract: A percutaneous absorption agent delivery device with: a solvent-impermeable cover film that has a first layer and a second layer, which are integrally continuous via a first fold and are superimposed, a non-seal region and a seal region are formed between the first layer and the second layer, the non-seal region disposed along the first fold, the seal region to surround the outer peripheral section of the non-seal region except for the section along the first fold, and an endless cut portion forming the non-seal region formed in the cover film; a percutaneous absorption agent carrying member is disposed in the non-seal region between the first layer and the second layer, and fixed to the cover film on the inner side of the cut portion; and an adhesive sheet that is detachably affixed to the outer surface of the cover film.

Abstract: The purpose of the present invention is to provide a nonaqueous tape that is stable and has high percutaneous absorption performance, and that contains pramipexole hydrochloride, which is slightly soluble in organic solvents and has high crystallinity. The present invention could produce a nonaqueous tape that is stable and has high percutaneous absorption performance by dissolving pramipexole, using a combination of a fatty acid ionic liquid and a divalent alcohol and a fatty acid ester. As a result, it has become possible to provide a transdermal patch (tape) containing pramipexole for the treatment of Parkinson's disease with which the problems associated with a conventional water-containing poultice of discoloration of the preparation and stability of the pramipexole can be solved.

Abstract: An object of the present invention is to provide a patch preparation having an excellent skin permeability of medicament using an acid additional salt of basic medicament. Provided is a patch preparation comprising a support and an adhesive layer on one surface of the support, wherein the adhesive layer contains a basic medicament, a fatty acid-based ionic liquid, and potassium salts and/or potassium ions. Said potassium salts and/or potassium ions are generated as a result of reaction of an acid addition salt of the basic medicament with a compound capable of generating potassium ion in the adhesive layer.

Abstract: Disclosed is a liquid preparation for external application, which has a shortened transdermal absorption lag time and has excellent transdermal absorption properties. Also, disclosed is a liquid preparation for external application, which is less irritative to skin. The problems can be solved by a transdermal liquid preparation containing: (a) propylene glycol in an amount of 40 to 98% by weight; (b) phosphatidylcholine in an amount of 0.1 to 5% by weight; (c) oleyl alcohol and/or isostearyl alcohol in an amount of 0.1 to 10% by weight; and (d) a medicine in an amount of 0.1 to 25% by weight. It is preferred that the transdermal liquid preparation additionally contains an alkanol amine. The alkanol amine is preferably triethanolamine.

Abstract: The present invention provides a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared.

Abstract: The present invention relates to a microneedle and a microneedle array. More specifically, it relates to a microneedle and a microneedle array capable of injecting a drug into the surface layer or horny layer of the skin easily, safely and efficiently.

Abstract: The embodiments provide a percutaneous absorption composition for a basic medicament having improved transdermal absorbability. The percutaneous absorption composition comprises a sorbic acid and/or a metal sorbate as a percutaneous absorption promoter. The molar ration of the sorbic acid and/or the metal sorbate to the basic medicament is 0.5-2.5. The composition of the present disclosure may further comprise a basic component.

Abstract: Provided is a novel delivery system for a percutaneous absorption drug preparation. The delivery system for a percutaneous absorption drug preparation is provided with: a solvent-impermeable first sheet; a solvent-impermeable second sheet that is bonded to the top surface of the first sheet and comprises a non-sealed area and a sealed area surrounding the non-sealed area, said non-sealed area and sealed area being formed between the first sheet and the second sheet, and a cutting part circularly extending along the outer peripheral edge of the non-sealed area; a percutaneous absorption drug preparation-holding member that is disposed between the first sheet and the second sheet in the non-sealed area and fixed to the second sheet inside the cutting part; and a pressure-sensitive adhesive third sheet that is removably bonded to the top surface of the second sheet.

Abstract: The purpose of the present invention is to provide an aqueous preparation for external use, said aqueous preparation comprising an acidic drug such as an arylacetic acid nonsteroidal anti-inflammatory analgesic, having an excellent percutaneous absorbability and giving a good feeling in use. The aqueous preparation for external use comprises the acidic drug or a salt thereof, isostearic acid and an alkanol amine. It is preferred that the aqueous preparation according to the present invention for external use further comprises a C2-6 aliphatic hydroxy acid and has a pH value of 4.5-7.8. The C2-6 aliphatic hydroxy acid is one member or a combination of the same selected from the group consisting of lactic acid, glycolic acid, malic acid, tartaric acid and citric acid.

Abstract: The invention provides an applicator that holds a microneedle to facilitate puncture of the skin and includes an assisting tool as a supporting base to set the microneedle and an adhesive sheet such as a tape and the like, on the side face of the assisting tool to enable close adhesion of the microneedle puncturing the skin.

Abstract: A microneedle and a microneedle array, which have both aspects of safety and easiness to use and can administer a predetermined dose of a medical agent without causing a pain by smoothly running into the skin surface layer of a patient, includes a frustum and a forward end portion thereon, the forward end portion having a forward end apex angle in the range of 15 to 60° and a forward end diameter in the range of 1 to 20 ?m and satisfying the expression H/D?5, where H is a total height of the microneedle, and D is a diameter of a bottom surface of the frustum).

Abstract: The purpose of the present invention is to provide a nonaqueous tape that is stable and has high percutaneous absorption performance, and that contains pramipexole hydrochloride, which is slightly soluble in organic solvents and has high crystallinity. The present invention could produce a nonaqueous tape that is stable and has high percutaneous absorption performance by dissolving pramipexole, using a combination of a fatty acid ionic liquid and a divalent alcohol and a fatty acid ester. As a result, it has become possible to provide a transdermal patch (tape) containing pramipexole for the treatment of Parkinson's disease with which the problems associated with a conventional water-containing poultice of discoloration of the preparation and stability of the pramipexole can be solved.

Abstract: A device for inserting needles of a microneedle patch into a skin includes a housing. The housing includes a support portion for supporting a microneedle patch, a pressure-receiving portion to which the user applies a force to press the microneedle patch against the skin, and a plurality of leg portions each having at its one end a connecting portion connected to the pressure-receiving portion and having at its other end a tip portion coming into contact with the skin. The housing is designed to deform when a force is applied to the pressure-receiving portion, to cause a tension in a portion of the skin facing the support portion.

Abstract: The object of the present invention is to provide a composition for a non-aqueous patch preparation having an excellent adhesibility which can sustainedly release a drug. The patch preparation of the present invention can improve the adhesibility thereof as well as the release property of a drug by the addition of powder ingredient (e.g. a filler). As a result, the long-time sustention of the adhesibility of patch preparations can achieve the improvement of the transdermal absorbability and the sustained release of a drug. By the use of a composition for a patch preparation comprising this powder ingredient, a drug, regardless of the type of a drug is dissolved in an organic solvent or an ionic liquid to prepare a drug solution comprising the organic solvent, the drug solution is incorporated into the non-aqueous patch preparation of the present invention, and thereby a preparation with the improved transdermal-absorbability and sustained release can prepared.

Abstract: The present invention provides an external preparation composition of transcription factor decoy of good skin permeability, the composition comprising a transcription factor decoy dissolved in a fatty acid-based ionic liquid obtained from a fatty acid having 2 to 20 carbon atoms and an organic amine compound having 4 to 12 carbon atoms.

Abstract: The present invention provides a microneedle array which makes it possible to quantitatively and accurately inject a drug into the skin. The present inventors have found that when a microneedle array is coated with a drug composition comprising a drug and an additive which has a Vickers hardness of about 3 or more, the removal of the drug can be avoided, and the drug can be surely inserted into the skin along with the microneedle array. As a result, the microneedle array coated with the drug composition of the present invention can be used in the fields in which the drug is required to be administrated with high quantitative performance even when the drug is contained in small amounts, e.g., the administration of a vaccine, and the scope of application of the microneedle array can be extended.

Abstract: Provided are a jig for uniformly applying a drug liquid to a microneedle, and a method of applying a drug to a microneedle using same. Grooves of a number corresponding to the number of rows of small needles of a microneedle are formed in the surface of a flat plate jig or of a roller-like jig, and a drug liquid is filled and held in the grooves. The drug liquid is applied to the microneedle by inserting the small needles of the microneedle into the surface of the drug liquid held in the narrow grooves, and immersing the small needles in the drug liquid. By this, the drug liquid is uniformly applied to the small needles of the microneedle without unevenness between the central section and the peripheral section of each microneedle, and thus the microneedles having good quality can be easily manufactured.

Abstract: The present disclosure provides a composition for a non-aqueous patch preparation with excellent adhesibility which can sustainedly release a drug. The patch preparation can improve the adhesibility of the patch preparation and the release property of a drug by the addition of a powder ingredient the long-time sustention of the adhesibility of tape preparations enables an improvement of the transdermal absorbability and the sustained release of a drug.

Abstract: [Summary] An external preparation formulation superior in the transdermal absorbability has been desired as a new administration route of aripiprazole. Transdermal absorption of aripiprazole has been enabled for the first time by appropriately combining aripiprazole and an organic acid (particularly fatty acid with low lipophilicity). That is, it has been found that more superior transdermal absorbability can be achieved by forming a salt by using a compound showing lipophilicity within the range of ?1.5-2, such as fatty acid and the like. It has been further found that the transdermal absorbability is remarkable improved by appropriately selecting the solvent composition. As a result, since a new dosage form of aripiprazole other than oral preparation has been developed, a new transdermal absorption preparation of aripiprazole can be provided.

Abstract: The present invention discloses a novel tape preparation containing lidocaine at a high concentration. A tape preparation containing lidocaine at a high content, which has a lidocaine content of 10 w/w % or more, can be produced by using a lactic acid salt of lidocaine, while preventing the precipitation of a crystal of lidocaine.